In the wake of #False #Tweets causing our share price to drop precipitously, I have purchased shares in the open market showing my commitment and firm belief in $TCBP & our goal of data in 1H 2025. This is on top of the prior shares I chose to take in place of cash compensation.

$TCBP Awarded Non-Dilutive Funding, Scaleready's G-Rex® $Grant #celltherapy #oncology ir.tcbiopharm.com/news/press-rel…

Congrats to Poseida Therapeutics on being acquired by Roche. After such a long freeze, it's great to see M&A activity in the Cell Therapy Space. prnewswire.com/news-releases/…

$TCBP appreciates being a part of the great work from the team Cell and Gene Therapy Catapult #CellTherapy Read the Report Here: cgt.ams3.cdn.digitaloceanspaces.com/GMP-Manufactur…

Our F3 filing (shelf) is NOT immediately dilutive. It's a placeholder that allows us to be opportunistic about good news with a positive market reaction. Filings, like the one we filed on Weds, are normal business practices for biotechs that are fundamental to accessing capital.

$TCBP Provides Quarterly Update on the #ACHIEVE (UK) #ClinicalTrial - Positive safety data, allowing for exploration of higher TCB008 doses - 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025 ir.tcbiopharm.com/news/press-rel…

$TCBP Partners with CareDx®, Inc. to Support #ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy ir.tcbiopharm.com/news/press-rel…

$TCBP Announces General Meeting of Shareholders to Approve One-Time #Shareholder #Dividend The dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the Company's stock at the close of trading on January 02, 2025. ir.tcbiopharm.com/news/press-rel…

$TCBP Advances ACHIEVE Phase 2b Clinical Trial with #Final #Dosing of 3 Patients finance.yahoo.com/news/tcbp-adva…

$TCBP Provides Update on #Acquisition Strategy and Current Targets finance.yahoo.com/news/tcbp-prov…

TCBP Trading Continues Unabated on Nasdaq Stock Exchange finance.yahoo.com/news/tcbp-trad…

$TCBP Announces #H5N1 Proof of Concept Studies Intention finance.yahoo.com/news/tcbp-anno…

LIVE LOOK - Bryan Kobel Presenting on $TCBP at the #Sequire Investor Summit

benzinga.com/general/biotec…

Congrats to Xilio Therapeutics, Inc. Great news to see M&A #Activity in the T-Cell space.

$TCBP Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum finance.yahoo.com/news/tcbp-ceo-…

$TCBP Announces Non-Binding Letter of Intent to #Acquire #Commercial #Stage Ophthalmic Pharmaceutical Company finance.yahoo.com/news/tcbp-anno…

🔮 2025 is going to be a big year for #biotech. On BBC News (UK), our CEO Sajith Wickramasekara explains why the industry is on the cusp of a faster, more automated, and #AI-driven future. 📺 Watch the full interview: benchling.com/news/opportuni…

$TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead The company is expected to reduce core operational burn by 55% when compared to 2024 ir.tcbiopharm.com/news/press-rel…

$TCBP Announces Grant of European #Patent for Targeting of Microbial, #Oncological, and Viral Indications using Modified Gamma Delta T Cells finance.yahoo.com/news/tcbp-anno…